Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent... Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.
- Mechanism
- Curator reviewed
As a benzopyrano-bipyridine carboxylic acid derivative, amlexanox has anti-inflammatory and antiallergic properties. It inhibits chemical mediatory release of the slow-reacting substance of anaphylaxis (SRS-A) and may have antagonistic effects on interleukin-3. When cells are under stress, they release an inactive form of human fibroblast growth factor 1 (FGF-1), a potent mitogen (entity that causes mitosis). Amlexanox binds to FGF1, increasing its conformational stability, sterically blocking Cu(2+) induced oxidation which normally leads to activation of FGF-1.
- Primary indication
- Used as a paste in the mouth to treat aphthous ulcers (canker sores).Curator reviewed
- Formula / weight
- C16H14N2O4 · 298.2934 g/mol (avg)
- First approval
- Canada, 2002
- Also known as
- Amoxanox
- Code names
- AA-673 · CHX-3673
Resolves to
SGRYPYWGNKJSDL-UHFFFAOYSA-NSMILESCC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1What you can answer from here — as of September 12, 2026
Which drugs share a target with Amlexanox, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account